
Roemerine
CAS No. 548-08-3
Roemerine( —— )
Catalog No. M31725 CAS No. 548-08-3
Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 508 | In Stock |
![]() ![]() |
50MG | Get Quote | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRoemerine
-
NoteResearch use only, not for human use.
-
Brief DescriptionRoemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
-
DescriptionRoemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number548-08-3
-
Formula Weight279.33
-
Molecular FormulaC18H17NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (358.00 mM)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
2,4-DIMETHYLTHIAZOLE
Compound Fr14565 is a useful organic compound for research related to life sciences.
-
Ergosterol peroxide
Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inhibiting pAKT and c-Myc and activating pro-apoptotic protein Puma and Bax to induce cancer cell death.
-
Abagovomab
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal antibody produced by hybridoma cells in mice that targets the tumor-associated antigen CA-125 and is used to study ovarian cancer.